["{\n\"step_by_step_thinking\": \"The patient is interested in including maraviroc in their maintenance regimen. Maraviroc is a CCR5 antagonist, which means it targets the CCR5 receptor on CD4 T cells. The article 'Update on HIV infection' discusses the epidemiology and transmission of HIV infection, but does not provide information about specific antiretroviral medications. However, articles like 'Pharmacologic treatment of the patient with acquired immunodeficiency syndrome' and 'HIV-1 infection. Diagnosis and management' provide information about various antiviral therapies, including maraviroc. Maraviroc specifically targets the CCR5 receptor, which is affected by the virus HIV-1. Therefore, to consider maraviroc for therapy, a tropism assay needs to be performed to determine if the patient's virus is CCR5-tropic.\",\n\"answer_choice\": \"B\""]